Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cystic Fibrosis
83%
Lung Function
35%
Continuous Positive Airway Pressure
33%
Cystic Fibrosis Transmembrane Conductance Regulator
29%
AE-IPF
28%
Preterm Infants
25%
Lung Growth
19%
Pulmonary Function Test
19%
Vitamin C
19%
Lubiprostone
18%
Mouse Lung
18%
Chloride Secretion
18%
Pregnant Smokers
18%
Intubation
18%
Premature Infant
18%
Early childhood
18%
Nasal Continuous Positive Airway Pressure
18%
Forced Expiratory Flow
16%
Lung
15%
Forced Expiratory Volume in 1 Second (FEV1)
15%
ClC-2
14%
Wheezing
14%
Neonatal Intensive Care Unit
14%
Vitamin C Supplementation
13%
Elexacaftor-tezacaftor-ivacaftor
13%
Respiratory Health
12%
Randomized Controlled Trial
12%
Gene Therapy
12%
Airway Function
12%
Pre-pregnancy Body Mass Index
11%
Intubated
11%
Lung Volume
11%
Cystic Fibrosis Foundation
11%
Spirometry
10%
Gestational Age
9%
Adjusted Means
9%
Pre-pregnancy Obesity
9%
Odds Ratio
9%
Asthma
9%
Drug Innovation
9%
Mutation Classes
9%
Randomized Controlled Clinical Trial
9%
Childhood Wheeze
9%
Acute Lung Disease
9%
Endocervix
9%
Chemically Modified mRNA
9%
Primary Snoring
9%
Inhaled Tobramycin
9%
Very Low Birth Weight Infant
9%
At Birth
9%
Medicine and Dentistry
Cystic Fibrosis
100%
Lung
57%
Continuous Positive Airway Pressure
30%
Messenger RNA
28%
Placebo
23%
Ascorbic Acid
22%
Offspring
22%
Oral
22%
Wheeze
21%
Cystic Fibrosis Transmembrane Conductance Regulator
21%
Solid Lipid Nanoparticle
21%
Prematurity
18%
Supplementation
18%
Lung Function Test
18%
Gene Therapy
12%
Tezacaftor
12%
Ivacaftor
12%
Silo-Filler's Disease
11%
Clinical Study
11%
Randomized Controlled Trial
11%
Chloride
11%
Spirometry
10%
In Vitro
10%
Diseases
10%
Forced Expiratory Flow
9%
Secretion (Process)
9%
Controlled Clinical Trial
9%
Tobramycin
9%
Amiloride
9%
Azithromycin
9%
Pharyngitis
9%
Very Low Birth Weight
9%
Chronic Lung Disease
9%
Pseudomonas aeruginosa
9%
Fatty Acid Desaturation
9%
Glucocorticoid
9%
Asthma
9%
Epithelial Sodium Channel
9%
COVID-19
9%
Neonatal Intensive Care Unit
9%
Low Drug Dose
9%
Bone Density
9%
Antiinfective Agent
9%
Health Care Cost
9%
Outpatient
9%
Haplorhini
9%
Patient with Cystic Fibrosis
9%
Growth Disorder
9%
Randomized Clinical Trials
9%
Hypoxemia
9%